Gilead Sciences Strengthens HIV Pipeline and Expands Oncology Ambitions

Gilead Sciences reports progress on a twice-yearly HIV injection and its Arcellx acquisition for CAR-T therapy. The stock is up ~19.5% YTD, with a dividend payment scheduled for March 2026.

Biopharmaceutical leader Gilead Sciences is making significant strides in its core HIV franchise while strategically building its oncology division. Recent developments highlight a dual focus: advancing a potentially revolutionary long-acting HIV therapy and expanding its cancer treatment portfolio through acquisition.

Strategic Acquisition to Broaden Oncology Footprint

Beyond its virology expertise, Gilead is actively diversifying its business. The company is progressing with its planned acquisition of the biotechnology firm Arcellx, with the transaction targeted for completion by the end of the second quarter of 2026. This move is designed to integrate a novel CAR-T cell therapy for treating multiple myeloma, thereby broadening Gilead's foundation in cancer research and reducing its historical reliance on the HIV market.

Promising Data for Biannual HIV Treatment

At a recent specialist conference in Denver, Gilead presented encouraging clinical data for its investigational drug, GS-3242. Early study results suggest this injectable therapy could be administered just twice a year, a stark contrast to current standard treatments which typically require daily oral tablets. The industry is heavily investing in such long-acting formulations, as they have the potential to greatly improve patient adherence to treatment regimens. For Gilead, success in this area is crucial to maintaining its market-leading position in HIV and modernizing its product portfolio.

Shareholder Returns and Market Performance

For investors, near-term corporate actions are also in view. The company's quarterly dividend is scheduled for payment on March 30, 2026. Shareholders must be on record by the ex-dividend date of March 13, 2026, to qualify for the payout.

On the markets, Gilead's stock has demonstrated resilience. Although shares experienced a modest decline of 0.83 percent on Friday, closing at 124.02 euros, they remain up approximately 19.5 percent since the start of the year. This performance keeps the equity within striking distance of its 52-week high of just over 131 euros.